Improving cardiovascular risk stratification: The case for redefining microalbuminuria

Journal of Nephrology

Volumn 20, Issue SUPPL. 12, 2007, Pages

  Leoncini, Giovanna ^a   Ratto, Elena ^a   Viazzi, Francesca ^a   Parodi, Angelica ^a   Falqui, Valeria ^a   Conti, Novella ^a   Tomolillo, Cinzia ^a   Deferrari, Giacomo ^a   Pontremoli, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cardiovascular risk; Hypertension; Microalbuminuria; Organ damage

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN; RENIN INHIBITOR;

ALBUMIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE MARKER; DRUG MECHANISM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEALTH SERVICE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MICROALBUMINURIA; OXIDATION; PREVALENCE; PREVENTIVE HEALTH SERVICE; PULSE WAVE; QUALITY OF LIFE; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 39449140051     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
2. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000; 35: 539-43.
3. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
4. Viazzi F, Parodi D, Leoncini G, Vettoretti S, Ratto E, Vaccaro V, Ravera M, Tomolillo C, Bezante GP, Del Sette M, Deferrari G, Pontremoli R. Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 2004; 22: 907-13.
5. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, Ruello N, Tomolillo C, Castello C, Grillo G, Sacchi G, Deferrari G. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997; 30: 1135-43.
6. Wachtell K, Dahlof B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, Gerdts E, Boman K, Bella JN, Devereux RB. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Am Heart J 2002; 144: 1057-64.
7. Pontremoli R, Ravera M, Bezante GP, Viazzi F, Nicolella C, Berruti V, Leoncini G, Del Sette M, Brunelli C, Tomolillo C, Deferrari G. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999; 17: 993-1000.
8. Mule G, Cottone S, Vadala A, Volpe V, Mezzatesta G, Mongiovi R, Piazza G, Nardi E, Andronico G, Cerasola G. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J Intern Med 2004; 256: 22-9.
9. Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V, Leoncini G, Ruello N, Zagami P, Bezante GP, Derchi LE, Deferrari G. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 1999; 14: 360-5.
10. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlof B, Ibsen H, Devereux RB. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 2004; 18: 453-9.
11. Leoncini G, Sacchi G, Viazzi F, Ravera M, Parodi D, Ratto E, Vettoretti S, Tomolillo C, Deferrari G, Pontremoli R. Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. J Hypertens 2002; 20: 1315-21.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
13. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension study. Hypertension 2005; 45: 198-202.
14. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-6.
15. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 11: 32-5.
16. Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 2006; 260: 231-7.
17. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-75.
18. Ratto E, Leoncini G, Viazzi F, Vaccaro V, Parodi A, Falqui V, Bezante GP, Tomolillo C, Deferrari G, Pontremoli R. Microalbuminuria and cardiovascular risk assessment in primary hypertension: should threshold levels be revised? Am J Hypertens 2006; 19: 728-34.
19. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
20. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22: 1805-11.
21. Sinzinger H, Kritz H, Furberg CD. Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance. Med Sci Monit 2003; 9: PI88-92.